On July 9, Ionis Pharmaceuticals fell 20.03% in regular trading, trading at $67.55/share, with turnover of $538 million. The sharp decline was triggered by the announcement that its drug Eplontersen failed to meet the primary efficacy endpoint in the Phase 3 Cardio-Ttransform trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

The trial, conducted in partnership with AstraZeneca, evaluated a composite endpoint of cardiovascular mortality and recurrent cardiovascular clinical events up to week 140 compared with placebo. The companies noted that in this contemporary patient population treated with standard of care, including a majority on a stabilizer, adding Eplontersen did not provide a statistically significant benefit. ATTR-CM is a core indication within Ionis's cardiometabolic pipeline, and this failure represents a major setback for the company's strategic positioning in that therapeutic area. AstraZeneca also declined over 8% on the same news. Notably, within the Biotechnology sector, competitors Alnylam Pharmaceuticals rose 9.31% and BridgeBio Pharma surged 14.38%, potentially reflecting a competitive repositioning as rival ATTR therapies gained favor.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)